However, if according to our results SSTR3 could be an interesting target for most NF-PitNETs, silent corticotroph tumors should be excluded for such a treatment, because of the low receptor levels they express, and therefore no positive results of SRLs treatment would be expectable in this tumor subtype. The gene discussed is SSTR3; the disease is neoplasm.